STUDY OF THE IMMUNOLOGICAL MARKERS CD49d AND CD38 IN EARLY-STAGE B-CLL PATIENTS

Slavcheva, Vanya; Blazheva, Svetla; Lukanov, Tzvetan; Naneva, Silvia; Tzvetkov, Nikolai

doi:10.5272/jimab.2018241.1883

Cited by 3 publications

(2 citation statements)

References 7 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the expression of these prognostic markers in the early stages and throughout the disease management may help identify progression. Popova et al ( 16 ) reported that flow cytometric markers were negative in the early stages of CLL and underwent changes in 10-25% of cases with disease progression. Previously, Saka et al ( 17 ) found that sCD23 determination at diagnosis and during the course of the disease may help identify patients who rapidly progress to more advanced stages.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of prognostic variables in chronic lymphocytic leukemia and association with disease stage

et al. 2021

View full text Add to dashboard Cite

The aim of the present study was to investigate different biological prognostic markers to identify high-risk patients with chronic lymphocytic leukemia (CLL) with a higher tumor burden, in order to ensure appropriate management. A total of 81 Egyptian patients with CLL were enrolled in the present study, with 75 healthy subjects serving as the control group. The expression of CD49d, CD38 and ZAP-70 in CLL cells was assessed using flow cytometry. The fluorescence in situ hybridization technique was employed to evaluate TP53 (del17p), ataxia-telangiectasia (del11q) and 13q14 (del13q14) genes and the presence of trisomy 12. The serological markers β2 microglobulin (B2M) and sCD23 were measured by ELISA. The CD49d gene was highly expressed in 25.9% and cytogenetic aberrations were observed in 66.6% of all recruited CLL patients. The patients were categorized according to the Binet staging system and a significant increase in the expression of sCD23, CD49d and ZAP-70 was detected in group C (P=0.008, 0.034 and 0.017, respectively) when compared to groups A and B. CD49d + patients exhibited significantly higher expression of CD38 (P=0.002) and trisomy 12 (P=0.015) and lower expression of del13q14 (P=0.001). Patients who were CD49d + with B2M>3.5 µg/ml exhibited higher total leukocyte count (P=0.048), higher absolute lymphocyte count (P=0.036), higher expression of CD38 (P=0.002) and trisomy 12 (P=0.034) and lower expression of del13q14 (P=0.002). Therefore, sCD23, CD49d and ZAP-70 may be considered as an optimal prognostic marker combination to be evaluated in the early stages of CLL and throughout disease management. Integrating both serological markers and CD49d expression by flow cytometry may add to the prognostic value of each marker alone and help identify high-risk patients with a higher tumor burden.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of prognostic variables in chronic lymphocytic leukemia and association with disease stage

et al. 2021

View full text Add to dashboard Cite

show abstract

“…CD49d is an adhesion molecule expressed on the surface of B lymphocytes (Popova, Blazheva, Lukanov, Naneva, & Tzvetkov, 2018), which can play a vital role in regulating cell-cell and cell-extracellular matrix interactions by binding to fibronectin and vascular cell adhesion molecule 1 (VCAM-1) in BM or GC (Hjalmar et al, 2002;Jurisic et al, 2005;Zhou et al, 2015). Increasing CD49d expression in Binet A CLL patients can be associated with reduced survival and poor response to treatment in these patients (Nuckel et al, 2009;Rossi et al, 2008).…”

Section: Cd49dmentioning

confidence: 99%

CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

Vosoughi

Bagheri

Hosseinzadeh

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is one of the most commonly occurring adult leukemias that is associated with clonal accumulation of mature apoptosis-resistant B-cells in bone marrow, peripheral blood, and specific tissues. Different pathogenesis factors can contribute to the aggression of the clinical course in this disease.Cytogenetic abnormalities and surface biomarkers of neoplastic CLL cells can be effective in the outcome of CLL, and the examination of changing CD markers expressions in the progression of CLL can be related to the prognosis of this disease. Changing expression levels of CD markers on lymphocytes and other cells in CLLpatients can play a role in the aggressive clinical outcomes such as organomegaly, immunodeficiency, and advanced disease stages through their interaction with CLL microenvironment. Given the involvement of CD markers in the pathogenesis of CLL, it can be stated that recognizing the expression changes of CD markers in the cells involved in CLL can be a proper approach to evaluate prognosis among these patients.

show abstract